Micafungin 100mg powder for solution for infusion vials
Requires a prescription from a doctor or prescriber
Micafungin is an antifungal drug.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Micafungin
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Micafungin
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Micafungin
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
7 branded products available
MHRA licensed products
View all licensed products for Micafungin on the MHRA register
Mycamine 100mg powder for solution for infusion vials
Micafungin 100mg powder for concentrate for solution for infusion vials
Micafungin 100mg powder for concentrate for solution for infusion vials
Micafungin 100mg powder for concentrate for solution for infusion vials
Micafungin 100mg powder for concentrate for solution for infusion vials
WHO defined daily dose (DDD)
100 mg
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via the NHS dm+d supplementary mapping files (NHSBSA). Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(1)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 14 · Randomised trials: 6 · 2009–2026
Showing the 50 most relevant studies, sorted by most relevant.
J. Timsit, É. Azoulay, C. Schwebel, et al.
JAMA, 2016
Xiping Li, Xiaoqin Liu, Juehui Mao, et al.
Pharmaceutics, 2024
Li X, Shao R, Zhang T, et al.
2026
- Antifungal Agents
- Hematopoietic Stem Cell Transplantation
- Invasive Fungal Infections
BackgroundInvasive fungal infections remain a major cause of morbidity and mortality among allogeneic hematopoietic stem cell transplantation recipients. There is still limited high-quality comparative evidence for antifungal agents.MethodsWe conducted a systematic review and network meta-analysis of randomized controlled trials and observational studies (PROSPERO: CRD420251270033), with databases search updated to September 2025. A prespecified assumption-based proportional imputation method was applied to estimate outcomes in mixed populations. Relative risks (RRs) were synthesized using a frequentist random-effects model, and treatments were ranked using surface under the cumulative ranking curve (SUCRA).ResultsThirty-two studies were selected, including 10 006 hematopoietic stem cell transplantation recipients. Across randomized controlled trials, posaconazole (RR, 0.19; 95% confidence interval, 0.08-0.44) and voriconazole (RR, 0.20; 95% confidence interval, 0.09-0.42) demonstrated the strongest efficacy against invasive fungal infections compared with placebo. Posaconazole ranked first for preventing invasive aspergillosis (SUCRA, 77.1%) and fungus-related mortality (SUCRA, 91.9%), while micafungin had the lowest discontinuation risk (SUCRA, 95.5%). Observational data favoured posaconazole tablets (SUCRA, 90.3%) over suspension (SUCRA, 75.2%). Isavuconazole showed lower hepatotoxicity-related discontinuation (5.3% vs. 22.9%; P = 0.0002), though these findings are based on limited cases. Trials implementing therapeutic drug monitoring showed a non-significant trend towards improved efficacy.ConclusionsPosaconazole and voriconazole demonstrate strong efficacy. Posaconazole tablets offer a favourable balance between benefit and risk. However, the potential safety benefits of isavuconazole warrant further evidence accumulation.
Abstract licence: CC BY-NC-ND
Shixia Xu, Zaiwen Zhang, Bo Feng, et al.
European review for medical and pharmacological sciences, 2016
Silvia Park, Kihyun Kim, J. Jang, et al.
The Journal of infection, 2016
Mariam John Amin Ibrahim, Marwa Saad Mohammed Fathy, Mertte Ashraf Thabet Ghobrial, et al.
Italian Journal of Pediatrics, 2025
S. Leroux, É. Jacqz-Aigrain, V. Elie, et al.
British Journal of Clinical Pharmacology, 2018
Wilke MH
European Journal of Medical Research, 2011
T. Oyake, S. Kowata, K. Murai, et al.
European Journal of Haematology, 2016
R. Wasmann, E. Muilwijk, D. Burger, et al.
Clinical Pharmacokinetics, 2017
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
14-17 hours
Mechanism
Micafungin inhibits the synthesis of beta-1,3-D-glucan, an essential component o…
Food interactions
None known
Human targets
None mapped
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
Half-life
14-17 hours
Protein binding
99%
Volume of distribution
0.11 L/kg
Metabolism
Elimination
28 days
Clearance
0.179 mL/min/kg
* 0.321…
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Indicated for the prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation.
Known interactions with other medicines. Always consult a healthcare professional.
Showing 22 of 22 interactions
Repeated daily doses up to 8 mg/kg (maximum total dose of 896 mg) in adult patients have been administered in clinical trials with no reported dose-limiting toxicity. The minimum lethal dose is 125 mg/kg in rats, equivalent to 8.1 times the recommended human clinical dose for esophageal candidiasis based on body surface area comparisons.
How the body processes this drug — absorption, distribution, metabolism, and elimination
* 0.321 +/- 0.098 mL/min/kg [HIV- Positive Patients with EC with 50 mg]
* 0.327 +/- 0.093 mL/min/kg [HIV- Positive Patients with EC with 100 mg]
* 0.340 +/- 0.092 mL/min/kg [HIV- Positive Patients with EC with 150 mg]
* 0.214 +/- 0.031 mL/min/kg [hematopoietic stem cell transplant recipients 3 mg/kg]
* 0.204 +/- 0.036 mL/min/kg [hematopoietic stem cell transplant recipients 4 mg/kg]
* 0.224 +/- 0.064 mL/min/kg [hematopoietic stem cell transplant recipients 6 mg/kg]
* 0.223 +/- 0.081 mL/min/kg [hematopoietic stem cell transplant recipients 8 mg/kg]
Enzymes involved in drug metabolism — important for understanding drug interactions
ATC J02AX05
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Micafungin
Additional database identifiers
Drugs Product Database (DPD)
20128
Drugs Product Database (DPD)
23698
ChemSpider
419105
BindingDB
50478216
UniProt Accession
FKS1_ASPNC
UniProt Accession
FKS2_YEAST
HUGO Gene Nomenclature Committee (HGNC)
HGNC:713
GenAtlas
ARSA
GeneCards
ARSA
GenBank Gene Database
X52151
UniProt Accession
ARSA_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2228
GenAtlas
COMT
GeneCards
COMT
GenBank Gene Database
M65212
GenBank Protein Database
180920
Guide to Pharmacology
2472
UniProt Accession
COMT_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite:
- DrugBank 6.02024Recommended citationKnox C., Wilson M., Klinger C.M., et alDrugBank 6.0: the DrugBank Knowledgebase for 2024Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
- DrugBank 5.02018Wishart D.S., Feunang Y.D., Guo A.C., et alDrugBank 5.0: a major update to the DrugBank database for 2018Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
- DrugBank 4.02014Law V., Knox C., Djoumbou Y., et alDrugBank 4.0: shedding new light on drug metabolismNucleic Acids Res. 2014 Jan 142(1):D1091-7
- DrugBank 3.02011Knox C., Law V., Jewison T., et alDrugBank 3.0: a comprehensive resource for 'omics' research on drugsNucleic Acids Res. 2011 Jan39(Database issue):D1035-41
- DrugBank 2.02008Wishart D.S., Knox C., Guo A.C., et alDrugBank: a knowledgebase for drugs, drug actions and drug targets.Nucleic Acids Research2008 Jan36(Database issue):D901-6
- DrugBank 1.02006Wishart D.S., Knox C., Guo A.C., et alDrugBank: a comprehensive resource for in silico drug discovery and exploration.Nucleic Acids Research2006 Jan 134(Database issue):D668-72